
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant advancements in scientific research, clinical trials, and regulatory landscapes within the industry. These developments are shaping the future of patient care and drug development significantly. Starting with Legend Biotech's LB2501, which achieved an impressive 100% response rate in a Phase 1 study for non-...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily

Moderna-Merck Combo Cuts Melanoma Risk by 49% | Pharma and Biotech Daily

Akeso's Ivonescimab Shows 34% Death Risk Cut at ASCO | Pharma and Biotech Daily

Pfizer's $10B Innovent Deal Boosts Cancer Drugs | Pharma and Biotech Daily
Free AI-powered recaps of Pharma and BioTech Daily and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.